Dr. John A. Pasquini, MD
Interventional Cardiology (Interventional Cardiology Physician)
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
NC license 29154 -
Cardiovascular Disease Physician
NC license 29154
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 917 | 532 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 342 | 313 |
| Established patient office or other outpatient visit, 20-29 minutes | 131 | 114 |
| Established patient office or other outpatient visit, 40-54 minutes | 37 | 34 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 28 | 28 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 17 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 14 | 14 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ezetimibe Other prescribers in Charlotte, NC | 341 |
| Rosuvastatin Calcium Other prescribers in Charlotte, NC | 294 |
| Atorvastatin Calcium Other prescribers in Charlotte, NC | 207 |
| Repatha Sureclick (evolocumab) Other prescribers in Charlotte, NC | 182 |
| Amlodipine Besylate Other prescribers in Charlotte, NC | 139 |
| Eliquis (apixaban) Other prescribers in Charlotte, NC | 129 |
| Metoprolol Succinate Other prescribers in Charlotte, NC | 113 |
| Carvedilol Other prescribers in Charlotte, NC | 96 |
| Losartan Potassium Other prescribers in Charlotte, NC | 89 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Charlotte, NC | 70 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $53,728 in research payments for these studies, mostly to the institutions running them.
- A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - LOWER: Lomitapide Observational Worldwide Evaluation Registry
Chiesi USA, Inc. · Completed · NCT02135705 - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.